news – Page 5696 – pharmaceutical daily

July 1, 2016 Off

AstraZeneca, LEO Pharma agree on Trolakinumab global rights deal

AstraZeneca has entered into an agreement with LEO Pharma A/S (LEO Pharma), a specialist in dermatology care, for the global licence to tralokinumab in skin diseases. As explained by AstraZeneca, Tralokinumab is a potential new medicine (an anti-IL-13 monoclonal antibody) that has completed a Phase IIb trial for the treatment of patients with atopic dermatitis, an inflammatory skin disease resulting in itchy, red, swollen and cracked skin.

April 8, 2016 Off

Allergan and Heptares team up for novel treatments in Alzheimer’s

By Dino Mustafić

Allergan and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation have entered into an agreement under which Allergan will license exclusive global rights to a broad portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological disorders, including Alzheimer’s disease.

April 8, 2016 Off

Biosimilars: More Treatment Options Are on the Way

By Dino Mustafić

As the medical market grows, the US Food and Drug Administration FDA has published a neat piece about biosimilars. Recently, FDA has approved a second biosimilar product—Inflectra (Infliximab-dyyb), a biosimilar to Remicade (infliximab)—and expects to approve other biosimilars in the future.

April 6, 2016 Off

Pfizer and Allergan scrap $160 bln deal

By Dino Mustafić

Pfizer and Allergan scrap $160 bln deal

April 6, 2016 Off

Primary Health Properties appoint new Directors

By Dino Mustafić

Primary Health Properties PLC, a UK-based investor in modern primary healthcare facilities, has appointed Geraldine Kennell and Nick Wiles to the Board as independent non-executive Directors.

April 5, 2016 Off

Diplomat’s Taltz approved for treatment of plaque psoriasis

By Dino Mustafić

TALTZ was recently approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe plaque psoriasis.

April 5, 2016 Off

New U.S. inversion rules threaten Pfizer-Allergan deal

By Dino Mustafić

The U.S. Treasury Department took new steps on Monday to curb tax-avoiding corporate “inversions,” with the pending $160 billion merger of Pfizer Inc and Allergan Plc seen as a potential casualty.

March 29, 2016 Off

Sanofi poaches AstraZeneca scientist as new research head

By Dino Mustafić

drugmaker Sanofi has poached one of AstraZeneca’s top scientists to be its new research head in another high-profile departure for the British drugmaker.

March 23, 2016 Off

AstraZeneca’s Brilianta tablets efficient in prevention of major vascular events

By Dino Mustafić

AstraZeneca on Wednesday announced the results of the SOCRATES trial, assessing the efficacy of Brilinta/Brilique (ticagrelor) 90 mg tablets twice daily, when compared to aspirin 100mg once daily in patients with acute ischaemic stroke or transient ischaemic attack (TIA)

March 22, 2016 Off

Drugmaker Valeant CEO leaving as investor Ackman joins the board

By Dino Mustafić

Drugmaker Valeant Pharmaceuticals International Inc said on Monday its chief executive officer is leaving and billionaire investor William Ackman would join the board as it tries to clean up accounting problems and save its business.